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Abstract
Background: HER2/neu is a member of the epidermal growth factor receptor family easily detectable in the serum
of cancer patients. We aimed to evaluate circulating HER-2 concentrations in association with insulin resistance in
healthy and obese subjects.
Methods: Insulin sensitivity (minimal model) and serum HER-2 concentrations were evaluated in a cross sectional
study in men (cohort 1, n = 167) and longitudinally after weight loss in obese subjects (cohort 2, n = 30).
Results: Serum HER-2 concentrations were positively associated with BMI and waist circumference (both r = 0.18, p
= 0.02), post-load glucose (r = 0.28, p = 0.001) and fasting triglycerides (r = 0.26, p = 0.001); and negatively
associated with insulin sensitivity (r = -0.29, p = 0.002, n = 109). Subjects with type 2 diabetes showed significantly
increased soluble serum HER-2 concentrations. In different multivariate regression models, fasting triglycerides
emerged as the factor that independently contributed to 10-11% of serum HER-2 variance.
Serum HER-2 concentrations correlated significantly with fasting triglycerides and insulin sensitivity index in sub-
jects from cohort 2. Weight loss led to a significant decrease of serum HER-2 concentrations. The change in serum
HER-2 concentrations were significantly associated with the change in percent body fat and fasting triglycerides in
young (below the median age of the cohort) subjects.
Conclusions: Serum HER-2 concentrations might be implicated in the pathophysiology of insulin resistance and
associated comorbidities.
Background
Some cancers -including those of the breast [1], colorec-
tum [2], endometrium [3], liver [4], and pancreas [5]
occur more commonly in individuals with diabetes. A
recent meta-analysis of 20 studies showed that women
with (versus without) diabetes had a statistically signifi-
cant 20% increased risk of breast cancer (RR, 1.20; 95%
CI, 1.12-1.28) [6].
The mechanisms underlying the relation between type
2 diabetes and breast cancer risk may be related to
alterations in circulating concentrations of insulin and
insulin-like growth factors (IGFs). It is well known that
insulin resistance and increased insulin secretion for
long periods are characteristics of type 2 diabetes both
before and after disease onset. Insulin has been
demonstrated to have mitogenic effects on breast tissue
[7,8], and insulin receptors are frequently over-expressed
in breast cancer cells [9,10]. A positive association
between circulating concentrations of insulin or C-pep-
tide and breast cancer risk has been observed in several
[11-15], but not in all epidemiologic studies [16-18]. Ele-
vated insulin concentrations may also stimulate tumor
growth by increasing bioavailable IGF-I [19]. High circu-
lating IGF-I concentrations have been shown to predict
premenopausal breast cancer risk [20].
The epidermal growth factor receptor (EGFR) family
was the first growth factor receptor to be identified in
cancer cells [21]. There are four members of the EGFR
family: EGFR, c-erbB-2 (HER2), erbB3 and erbB4. The
unligated, monomeric receptor does not appear capable
of signalling. The receptors need to oligomerize -usually
in response to ligands- before intracellular signalling is
initiated. Each family member has unique characteristics:
the EGFR binds ligands and its kinase is activated by
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asymmetric interactions with the other family members
[22].
HER2 (also known as neu and as c-erbB-2, which
encodes a Mr185,000 transmembrane glycoprotein
receptor) is a proto-oncogene of the EGF receptor
family of receptor tyrosine kinases that does not bind
ligands but is poised to associate with ligand-activated
forms of the other family members [22]. These receptors
are composed of an extracellular binding domain, a
transmembrane lipophilic segment, and an intracellular
protein tyrosine kinase domain with a regulatory car-
boxyl terminal segment [23]. Full-length HER2 under-
goes a proteolytic event that results in the release of the
soluble ECD/HER-2 fragment and, concomitantly, in the
production of an amino-terminally truncated, cell-asso-
ciated, HER2 fragment that contains the kinase domain
(designated as HER2 p95 because of its molecular
weight) with enhanced signaling activity [24].
ECD/HER-2 can be released by proteolytic cleavage
from the full-length HER2 receptor. Like EGFR, it is a
tyrosine kinase receptor whose activation leads to prolif-
erative signals within the cells. Because HER-2 is the
preferred dimerization partner when heterodimers are
formed, it is important for signaling through ligands
specific for any members of the family. Levels of circu-
lating ECD/HER-2 are easily detectable in the serum of
breast cancer patients and its measurement has been
proved useful to monitor women with metastatic breast
cancer, to detect the early appearance of recurrent
breast cancer and to predict response to hormonal ther-
apy or chemotherapy [25,26]. Recently, we have found
that metformin led to down-regulation of HER-2
expression in in vitro models [27]. We hypothesised that
the change in insulin action induced by metformin was
behind this observation. If this was the case, systemic
insulin action might interact with circulating HER-2
concentration. We thus aimed to evaluate circulating
HER-2 concentration in association with insulin sensi-
tivity in a cross-sectional study in healthy men, and in a
longitudinal study in obese subjects.
Methods
Cohort 1 Subjects
One hundred and seventy-seven consecutive men fulfill-
ing inclusion criteria and enrolled in a cross-sectional,
population-based study on cardiovascular risk factors in
healthy subjects in Northern Spain were studied. All
subjects were of Caucasian origin and reported that
their body weight had been stable for at least three
months before the study. None of the patients were tak-
ing any medication or had any evidence of metabolic
disease other than obesity. A 75-g oral glucose tolerance
test according to the American Diabetes Association
Criteria was performed in all subjects. Of these subjects,
100 had strictly normal glucose tolerance, 38 showed
impaired glucose tolerance and 29 had previously
unknown type 2 diabetes (either in fasting conditions or
during the oral glucose tolerance test).
Inclusion criteria for all subjects were: 1) body mass
index (BMI) < 40 kg/m2, 2) absence of any systemic dis-
ease, 3) alcohol intake less than 40 g a day. Informed
written consent was obtained after the purpose, nature,
and potential risks were explained to the subjects. The
protocol was approved by the Hospital Ethics
Committee.
Measurements
Each subject was studied in the research laboratory in
the fasting state. Patients were requested to withhold
alcohol and caffeine during at least 12 h prior to the
insulin sensitivity test. Insulin sensitivity was measured
using the frequently sampled intravenous glucose toler-
ance test in those subjects who agreed (n = 109 of
Cohort 1 subjects), as previously described [28].
Study of the effects of weight loss
Forty-two Caucasian obese volunteers (22 females, 20
males) attending the Endocrinology Department at the
University Clinic of Navarra were recruited. Patients
underwent a clinical assessment including medical his-
tory, physical examination, body composition analysis,
co-morbidity evaluation as well as nutritional interviews
performed by a multidisciplinary consultation team. All
subjects were non-smokers. Patients with signs of infec-
tion were excluded. Obese patients were not receiving
statins or antidiabetic medication.
Weight loss was achieved by prescription of a diet
providing a daily energy deficit of 500-1000 kcal/d as
calculated from the determination of the resting energy
expenditure through indirect calorimetry (Vmax29, Sen-
sorMedics Corporation, Yorba Linda, California) and
multiplication by 1.4 as indicated for sedentary indivi-
dual’s to obtain the patient’s total energy expenditure.
This hypocaloric regime allows a safe and steady weight
loss of 0.5-1.0 kg/wk when followed and supplied 30, 54
and 16% of energy requirements in the form of fat, car-
bohydrates and protein, respectively.
In this study, body weight was measured with a digital
scale to the nearest 0.1 kg, and height was measured to
the nearest 0.1 cm with a Holtain stadiometer (Holtain
Ltd., Crymych, UK). Body fat was estimated by air-dis-
placement-plethysmography (Bod-Pod®, Life Measure-
ments, Concord, California, USA). Data for estimation
of body fat by this plethysmographic method has been
reported to agree closely with the traditional gold stan-
dard hydrodensitometry (underwater weighing).
The institutional review board of the participant insti-
tutions approved the protocol, so we certify that all
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applicable institutional regulations concerning the ethi-
cal use of information and samples from human volun-
teers were followed during this research.
Analytical determinations
The serum glucose concentrations were measured in
duplicate by the glucose oxidase method with the use of
a Beckman Glucose Analyzer II (Beckman Instruments,
Brea, Calif). Total serum cholesterol was measured
through the reaction of cholesterol esterase/cholesterol
oxidase/peroxidase, using a BM/Hitachi 747. HDL cho-
lesterol was quantified after precipitation with polyethy-
lene glycol at room temperature. Total serum
triglycerides were measured through the reaction of gly-
cerol-phosphate-oxidase and peroxidase. HbA1c was
measured by the high-performance liquid chromatogra-
phy method (Bio-Rad, Muenchen, Germany, and autoa-
nalyser Jokoh HS-10, respectively). Intra- and inter-assay
coefficients of variation were less than 4% for all these
tests.
Serum insulin was measured in duplicate by monoclo-
nal immunoradiometric assay (Medgenix Diagnostics,
Fleunes, Belgium). The intra-assay coefficient of varia-
tion was 5.2% at a concentration of 10 mU/l and 3.4%
at 130 mU/l. The inter-assay coefficients of variation
were 6.9% and 4.5% at 14 and 89 mU/l, respectively.
In the effects of weight loss study, plasma glucose was
analyzed by an automated analyzer (Roche/Hitachi
Modular P800) as previously described [29] Insulin was
measured by means of an enzyme-amplified chemilumi-
nescence assay (IMMULITE®, Diagnostic Products
Corp., Los Angeles, CA, USA). To estimate insulin resis-
tance, the HOMA index was calculated as fasting insulin
concentration (μU/mL) × fasting glucose concentration
(mmol/L)/22.5.
HER2-specific enzyme-linked immunosorbent assay
Determinations of circulating HER2 concentrations were
centralized in a single laboratory and performed with a
commercially available quantitative ELISA (Oncogene
Science, Bayer Diagnostics) according to the manufac-
turer’s protocol. Intra- and interassays coefficients of
variation were lower than 8%. Two controls (high and
low, as provided by the manufacturer) were run in each
assay to confirm that recoveries fell within the expected
ranges (9.8 ± 0.69 and 3.3 ± 0.34 ng/ml, respectively)
for each level. Free IGF-I was determined using a 2-site
immunoradiometric assay (IRMA) kit (Diagnostic Sys-
tems Laboratories; Webster, TX). The detection limit
was 0.03 ng/mL, with an intra-assay variation less than
10% for concentrations below 2 ng/mL.
Statistical methods
Descriptive results of continuous variables are
expressed as mean ± SD. Before statistical analysis,
normal distribution and homogeneity of the variances
were evaluated using Levene’s test and then variables
were given a log-transformation if necessary. These
parameters (triglycerides, insulin sensitivity, and serum
HER-2) were analyzed on a log scale and tested for
significance on that scale. Relation between variables
were tested using Pearson’s test and stepwise multiple
linear regression analysis. We used chi-square test for
comparisons of proportions, and ANOVA test with
post-hoc Sheffé’s test for comparisons of quantitative
variables across categories of glucose tolerance. For a
given value of p = 0.05, the study had a 99% power to
detect significant correlations between parameters in
the whole sample of subjects in a bilateral test (n =




Anthropometric and biochemical characteristics of the
Cohort 1 men are shown in Table 1. Serum HER-2 con-
centrations were positively associated with BMI and
waist circumference (both r = 0.18, p = 0.02), post-load
glucose (r = 0.28, p = 0.001), glycated hemoglobin (r =
0.16, p = 0.03), total cholesterol (r = 0.23, p = 0.003),
LDL-cholesterol (r = 0.20, p = 0.01) and fasting trigly-
cerides (r = 0.26, p = 0.001, Figure 1); and negatively
associated with free IGF-I (r = -0.26, p = 0.001) and
insulin sensitivity (r = -0.29, p = 0.002, Figure 1). Serum
HER-2 concentrations were not associated with age,
fasting glucose or HDL-cholesterol (r < 0.12, p > 0.1).
Subjects with type 2 diabetes showed significantly
decreased insulin sensitivity and significantly increased
soluble serum HER-2 concentration (Table 1 and Figure
2).
In different multivariate regression models, fasting
triglycerides emerged as the factor that independently
contributed to 10-11% of serum HER-2 variance (Table
2).
Cohort 2. Weight loss study
Characteristics of the subjects are shown in Table 3.
Men and women were similar in age (45.2 ± 15.9 vs. 45
± 14.5 years, p = 0.9) and BMI (37.2 ± 9.5 vs. 36 ± 9.8
kg/m2, p = 0.7). Interestingly, circulating HER-2 concen-
tration was significantly increased in men (11.9 ± 1.9 vs.
8.5 ± 2.1 ng/ml, p < 0.0001) in parallel to insulin resis-
tance (HOMA value 5.2 ± 3.2 vs. 2.18 ± 1.5 in men and
women, respectively, p = 0.03). Serum HER-2 concen-
trations were significantly associated with fasting trigly-
cerides and HOMA value in this cohort of obese
subjects (Figure 1, right panels). Weight loss led to a
significant decrease in serum HER-2 concentrations in
parallel to changing anthropometric and metabolic
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Table 1 Clinical and biochemical variables of Cohort 1 subjects
Normal glucose tolerance Impaired glucose tolerance Type 2 diabetes ANOVA p
N 100 38 29 -
Age [years] 50.7 ± 13 59.6 ± 10.2 58 ± 12.1 <0.0001
BMI [kg/m2] 26.8 ± 3.3 28.3 ± 3.4 31.8 ± 6.9 <0.0001
Waist [cm] 90.4 ± 8.6 94.3 ± 9.1 104.6 ± 15.3 <0.0001
Systolic blood pressure [mm Hg] 124.7 ± 13 132.4 ± 17.3 138.8 ± 16.4 <0.0001
Diastolic blood pressure [mm Hg] 79 ± 9.1 83 ± 10.4 84.2 ± 11 0.03
Cholesterol [mg/dl] 205.5 ± 40.3 227.4 ± 41.7 211.8 ± 34.8 0.01
LDL-cholesterol [mg/dl] 132.8 ± 37.2 149.2 ± 34.6 129.3 ± 37.8 0.03
HDL- cholesterol [mg/dl] 53 ± 12.4 51.4 ± 11.5 47.3 ± 12 0.09
Log-Triglycerides [mg/dl] 1.94 ± 0.21 2.06 ± 0.21 2.13 ± 0.25 <0.0001
Fasting glucose [mg/dl] 95 ± 9.8 102.3 ± 11.5 138.5 ± 23 <0.0001
Fasting insulin [mU/l] 8 ± 4 12.1 ± 6.2 14.3 ± 9.7 <0.0001
HbA1c [%] 4.8 ± 0.55 4.9 ± 0.4 5.9 ± 1 <0.0001
120’ OGTT glucose [mg/dl] 108.3 ± 19.3 164.4 ± 19.4 233.2 ± 21.7 <0.0001
Log Insulin sensitivity [min-1*10-4*mU/L]* 0.58 ± 0.19 0.38 ± 0.17 0.16 ± 0.16 <0.0001
Free IGF-I [ng/ml] 1.51 ± 1.13 1.20 ± 1.05 0.47 ± 0.56† <0.0001
HER-2 [ng/ml] 9.6 ± 2.2 10.4 ± 1.8 11.4 ± 1.9† <0.0001
Expressed as mean ± SD; *determined in 72 subjects with normal glucose tolerance, 26 with impaired glucose tolerance and 11 with type 2 diabetes.
Post-hoc analyses
†p < 0.0001 after Sheffé’s test compared with subjects with normal glucose tolerance.
Figure 1 Linear relationhip between serum HER-2 concentration and log-fasting triglycerides and insulin resistance in subjects from
Cohort 1 [left panels] and in subjects from the weight loss study [Cohort 2, right panels].
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parameters (Table 3). The decrease in circulating HER-2
was significant in both men (from 11.9 ± 1.9 to 9 ± 1.9
ng/ml, p = 0.001) and women (from 8.5 ± 2.1 to 7.5 ±
1.3 ng/ml, p = 0.03).
The change in serum HER-2 concentrations was not
significantly associated with the change in BMI, percent
body fat, insulin resistance or fasting triglycerides (r <
0.2, p > 0.05) in the whole cohort of subjects. However,
when the subjects were divided according to the median
age of the cohort (46 years), we found that changing
serum HER-2 concentrations were significantly asso-
ciated with the change in percent body fat and fasting
triglycerides only in subjects aged less than 46 years
(Figure 3).
Discussion
Serum HER-2 concentrations are proportional to tissue
HER-2 signalling activity [24]. We here describe that cir-
culating HER-2 concentrations were positively asso-
ciated with insulin resistance and fasting triglycerides in
2 cohorts of subjects. In different multiple linear regres-
sion analyses, fasting triglycerides constituted and inde-
pendent factor that best explained the variance of
circulating HER-2 in cohort 1 subjects. Furthermore,
weight loss led to significantly decreased serum HER-2
concentrations. This decrease was especially remarkable
in young subjects (arbitrarily defined as those below the
median age of the cohort studied) in whom serum HER-
2 concentration decreased from 11.1 ± 2.9 to 7.8 ± 1.7
ng/ml (p < 0.0001), while this decrease did not reach
Figure 2 95% confidence interval for the mean of serum HER-2 according to glucose tolerance status in subjects from the Cohort 1
study.
Table 2 Multiple linear regression analyses with
circulating HER-2 as dependent variable Serum glucose
120’OGTT, serum glucose at 120 mins of the oral glucose
tolerance test
Dependent variable CIRCULATING HER-2
Independent Variables Beta Sig. Beta Sig. Beta Sig.
Age 0.03 0.7
BMI 0.08 0.37 0.015 0.9 -0.017 0.87
Serum glucose at 120’
OGTT
0.15 0.25
Log insulin sensitivity -0.19 0.057 -0.08 0.56 -0.20 0.09
Fasting triglycerides 0.31 0.001 0.23 0.03 0.24 0.01
Adjusted R2 0.11 0.11 0.11
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statistical significance in older subjects (9.77 ± 2.3 vs.
8.7 ± 1.6 ng/ml, p = 0.09). The decrease in young sub-
jects was in parallel to decreased body fat and fasting
triglycerides. The significance of this age-discordant
effects remains to be established in a larger cohort of
subjects. It should be recognized that the number of
subjects studied is relatively small and the findings
observed might be limited by study size. In cancer
patients, the association between hormonal receptors
and HER2/neu overexpression also varies with age. The
hormone receptors are not an independent predictor for
the HER2/neu status in young women while they are in
elder patients [30].
A positive association between circulating concentra-
tions of insulin or C-peptide and breast cancer risk has
been observed in several [11-15], but not in all epide-
miologic studies [16-18]. Type 2 diabetic patients in the
present study showed both increased fasting insulin and
serum HER-2 concentrations, two factors that may
potentially increase cancer risk.
Table 3 Subjects’ characteristics in the weight loss study
Baseli[ne Post-weight
loss
Number of participants 30 [15 men, 15 women]
Age [years] 45.1 ± 14.9
BMI [kg/m2] 36.6 ± 9.5 30.3 ± 5.4 <0.0001
Percent body fat [%] 43.7 ± 8.6 35 ± 9.6 <0.0001
WHR 0.96 ± 0.09 0.93 ± 0.07 0.02
SBP [mmHg] 128.2 ±
17.7
122 ± 14.9 0.1
DBP [mmHg] 81.8 ± 10.1 77.2 ± 7.5 0.04
Fasting glucose [mg/dl] 96 ± 11.9 89.8 ± 8.3 0.01
Insulin [mU/l] 18 ± 13 12 ± 6.1 0.04
Total cholesterol [mg/dl] 204.4 ±
35.7
175.6 ± 25.3 <0.0001
HDL-cholesterol [mg/dl] 53.2 ± 13.7 51.4 ± 12.8 0.3
LDL-cholesterol [mg/dl] 125.6 ±
32.8
108.6 ± 22 0.009
Log 10 Fasting
Triglycerides
2.00 ± 0.17 1.87 ± 0.16 <0.0001
HOMA-IR 4.1 ± 3.4 2.5 ± 1.3 0.04
HER-2 [ng/ml] 10.2 ± 2.6 8.2 ± 1.8 <0.0001
Figure 3 Linear relationship between changing serum HER-2 concentrations, changing body fat [upper panels] and triglycerides
[lower panels] according to the median age of the cohort.
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The mechanism behind the associations described
here should be explored further. In this sense, it is
important to note that Hsp90 regulates the intracellular
trafficking and stability of both nascent HER-2 [31] and
insulin and IGF-I receptors [19]. On the other hand, in
patients with leprechaunism there are functional
abnormalities of the EGF receptor, as well as of the
insulin receptor, coined as multiple growth factor-resis-
tant syndrome, that may contribute to the severity of
the syndrome [32]. An interesting question raised by
these studies was whether insulin resistance could lead
to modulation of other receptors’ function. In fact, evi-
dence of EGF receptor abnormalities in several animal
models of diabetes has been reported. Ob/ob and db/db
mice were found to have a 70-80% decrease in EGF
binding in liver membranes associated with decreased
EGF receptor phosphorylation and decreased EGF
receptor mRNA levels [33]. EGF binding and receptor
phosphorylation was observed to be reduced in liver
membranes from streptozotocin-treated diabetic rats
[34]. The meaning of increased circulating HER-2 in a
scenario of insulin resistance (current findings) should
be explored further.
Metformin led to down-regulation of HER-2 in in vitro
models [27], and overexpression of fatty acid synthase
gene (implicated in the synthesis of endogenous fatty
acids and triglycerides) activated HER1/HER2 tyrosine
kinase receptors in human breast epithelial cells [35].
Regarding other potential mechanisms, cleavage of the
HER2 ectodomain is a process that is inhibited by the
tissue inhibitor of metalloproteases-1 [24]. Taking into
account this information, we explored the association of
circulating HER-2 with other circulating molecules
whose concentrations are dependent on the activity of
metalloproteases. Interestingly, in patients with type 2
diabetes, serum HER-2 concentrations were positively
associated with serum soluble tumor necrosis factor-a
(TNF-a) receptor 1 [r = 0.65, p = 0.001, n = 21] and
serum DLK-1 (r = 0.81, p = 0.007, n = 9) (data not
shown). In fact, TNF-a caused a dose-dependent
decrease in insulin-stimulated IRS-1 phosphorylation
and EGF-stimulated receptor autophosphorylation to
47-50% of control in in vitro studies. It could be specu-
lated that TNF-a might be behind concomitant insulin
resistance and EGF resistance, leading to increased cir-
culating HER-2 levels [36].
Other members of the epidermal growth factor (EGF)
family (neuregulins, which bind erb3 and erb4 receptors)
modulate muscle metabolism by inducing glucose
uptake, independently of insulin [37], and by regulating
glucose transporter expression [38]. In fact, anti-neure-
gulin receptor-blocking antibodies impair contraction-
induced glucose uptake [39]. Betacellulin-delta4 also
ameliorates glucose intolerance in streptozotocin-treated
rats [40].
The strenghts of this manuscript are the study of an
homogenous sample of subjects and the use of a strong
measure of insulin sensitivity (minimal model method)
in cohort 1’s subjects. Limitations include the evaluation
of men in cohort 1 and of men and women in cohort 2.
In summary, circulating HER-2 concentrations were
associated with insulin resistance in healthy subjects,
significantly increased in patients with type 2 diabetes
and decreased after weight loss in obese subjects. The
role of serum HER-2 concentrations in the pathophy-
siology of insulin resistance and associated co-morbid-
ities should be explored further.
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